LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Clinical trials for LOCALLY ADVANCED OR METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED OR METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED OR METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced breast cancer: experimental combo enters final testing
Disease control OngoingThis Phase 3 trial tests whether an experimental drug called SIM0270 combined with everolimus works better than standard treatments for people with ER+/HER2- advanced or metastatic breast cancer that has worsened after CDK4/6 inhibitor therapy. About 460 participants will be rand…
Matched conditions: LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE3 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New combo therapy aims to slow advanced breast cancer growth
Disease control OngoingThis study tests whether adding the drug giredestrant to standard treatment (Phesgo) can help people with advanced HER2-positive, estrogen receptor-positive breast cancer live longer without their cancer getting worse. About 922 participants who have not had prior treatment for a…
Matched conditions: LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for advanced breast cancer: drug combo targets resistant tumors
Disease control OngoingThis study tests a combination of two drugs, capivasertib and fulvestrant, in 101 people with a specific type of advanced breast cancer (HR+/HER2-) that has stopped responding to hormone therapy and a CDK4/6 inhibitor. The goal is to see how long it takes before the next cancer t…
Matched conditions: LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC